BioCryst Pharmaceuticals, Inc. (BCRX)
8.17
+0.05
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
8.15
-0.02
(-0.24%)
After-Hours: 20:00
BioCryst Pharmaceuticals Enterprise Value : 2.569B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.569B |
| October 01, 2026 | 2.556B |
| September 30, 2026 | 2.610B |
| September 29, 2026 | 2.595B |
| September 28, 2026 | 2.646B |
| September 25, 2026 | 2.676B |
| September 24, 2026 | 2.658B |
| September 23, 2026 | 2.671B |
| September 22, 2026 | 2.725B |
| September 21, 2026 | 2.720B |
| September 18, 2026 | 2.699B |
| September 17, 2026 | 2.704B |
| September 16, 2026 | 2.635B |
| September 15, 2026 | 2.567B |
| September 14, 2026 | 2.584B |
| September 11, 2026 | 2.556B |
| September 10, 2026 | 2.600B |
| September 09, 2026 | 2.731B |
| September 08, 2026 | 2.798B |
| September 04, 2026 | 3.026B |
| September 03, 2026 | 3.059B |
| September 02, 2026 | 3.080B |
| September 01, 2026 | 3.016B |
| August 31, 2026 | 2.960B |
| August 28, 2026 | 2.990B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.003B |
| August 26, 2026 | 2.993B |
| August 25, 2026 | 2.993B |
| August 24, 2026 | 2.955B |
| August 21, 2026 | 2.921B |
| August 20, 2026 | 2.949B |
| August 19, 2026 | 3.054B |
| August 18, 2026 | 2.960B |
| August 17, 2026 | 3.021B |
| August 14, 2026 | 2.970B |
| August 13, 2026 | 2.988B |
| August 12, 2026 | 3.187B |
| August 11, 2026 | 3.123B |
| August 10, 2026 | 2.995B |
| August 07, 2026 | 2.878B |
| August 06, 2026 | 2.858B |
| August 05, 2026 | 2.799B |
| August 04, 2026 | 2.786B |
| August 03, 2026 | 2.732B |
| July 31, 2026 | 2.776B |
| July 30, 2026 | 2.842B |
| July 29, 2026 | 2.916B |
| July 28, 2026 | 2.970B |
| July 27, 2026 | 2.929B |
| July 24, 2026 | 2.868B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 261.20B |
| Halozyme Therapeutics, Inc. | 14.44B |
| Neurocrine Biosciences, Inc. | 14.56B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| Agenus, Inc. | 620.93M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 78.40M |
| Revenue (Quarterly) | 218.25M |
| Total Expenses (Quarterly) | 139.86M |
| EPS Diluted (Quarterly) | 0.2957 |
| Gross Profit Margin (Quarterly) | 98.01% |
| Profit Margin (Quarterly) | 35.92% |
| Earnings Yield | -18.41% |
| Operating Earnings Yield | 19.89% |
| Normalized Earnings Yield | 6.835 |